R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

Abstract The use of non‐pegylated liposomal doxorubicin (Myocet®) in diffuse large B‐cell lymphoma (DLBCL) has been investigated in retrospective and single‐arm prospective studies. This was a prospective phase 2 trial of DLBCL patients ≥60 years old with left ventricular ejection fraction (LVEF) ≥5...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Juan‐Manuel Sancho, Rubén Fernández‐Alvarez, Francisco Gual‐Capllonch, Esther González‐García, Carlos Grande, Norma Gutiérrez, María‐Jesús Peñarrubia, Ana Batlle‐López, Eva González‐Barca, José‐María Guinea, Eva Gimeno, Francisco‐Javier Peñalver, Miguel Fuertes, Mariana Bastos, José‐Ángel Hernández‐Rivas, José‐María Moraleda, Olga García, Marc Sorigué, Alejandro Martin
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Wiley 2021-02-01
Rangatū:	Cancer Medicine
Ngā marau:	cardiotoxicity diffuse large B‐cell lymphoma liposomal doxorubicin N‐terminal pro‐B‐type natriuretic peptide troponin
Urunga tuihono:	https://doi.org/10.1002/cam4.3730
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!